Advancements in Bioactive Compounds and Therapeutic Agents for Alopecia: Trends and Future Perspectives

This review highlights significant advances in understanding and treating Alopecia Areata, emphasizing the effectiveness of JAK inhibitors like baricitinib, ritlecitinib, and deuruxolitinib for systemic treatment, while also noting ongoing research into new therapeutic approaches such as stem cell therapy and energy-assisted drug delivery.

This review reports that ritlecitinib, baricitinib, and deuruxolitinib, all JAK inhibitors, are effective treatments for moderate-to-severe alopecia areata, with differences in selectivity and onset of action, and suggests that emerging biologic therapies may enhance treatment by offering more targeted immune modulation.

This article discusses hair loss disorders, underscoring the recent therapeutic advance of ritlecitinib, approved for severe alopecia areata in individuals aged 12 and older, and the ongoing need to manage expectations given limited treatment options.

This review discusses recent advances and ongoing clinical trials in novel therapeutics for alopecia areata, despite the lack of current FDA-approved treatments for severe cases, and reports no new results.

In this study, JAK inhibitors were reported as safe and effective treatments for moderate-to-severe chronic alopecia areata, although the appropriate duration of treatment remains uncertain, as stopping these medications often results in relapse.